{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:51:55Z","timestamp":1781589115512,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravenous (IV) iron is associated with a low risk of adverse drug reactions (ADR); however, the risk varies by formulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 10\u2010year retrospective cohort study of Veterans Health Administration data was conducted to detect the cumulative incidence of any documented ADR, potentially serious ADR, and anaphylaxis to five IV iron formulations. Patients with any exposure to each of the five IV iron formulations were identified and assessed for subsequent ADR documentation listed to the same IV iron formulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 133\u2009588 patients were exposed to 162\u2009457 unique IV iron formulations. The overall documented IV iron ADR cumulative incidence was 79 events per 10\u2009000 (0.79%; 95% CI: 0.75%\u20130.84%). The potentially serious documented IV iron ADR cumulative incidence was 63 events per 10\u2009000 (0.63%; 95% CI: 0.60%\u2013 0.67%). The lowest cumulative incidence of documented ADR was associated with ferric carboxymaltose with 24 events per 10\u2009000 (0.24%; 95% CI: 0.15%\u2013 0.4%). Iron dextran was associated with the highest cumulative incidence of documented ADR with 189 events per 10\u2009000 (1.89%; 95% CI: 1.74%\u2013 2.05%). Iron dextran was also associated with the highest cumulative incidence of potentially serious ADR with 153 events per 10\u2009000 (1.53%; 95% CI: 1.39%\u2013 1.68%) and the highest cumulative incidence of documented anaphylaxis with 36 events per 10\u2009000 (0.36%; 95% CI: 0.3%\u2013 0.43%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study finds varying risk of documented potentially serious ADR and anaphylaxis between available IV iron formulations and aligns with previous data suggesting iron dextran is associated with a higher risk of serious ADR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70411","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:18:54Z","timestamp":1781482734000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Documented Adverse Reactions to Different Intravenous Iron Formulations in the Veterans Health Administration: A 10\u2010Year Retrospective Study"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0310-3395","authenticated-orcid":false,"given":"Ali","family":"Khalaf","sequence":"first","affiliation":[{"name":"Pharmacy Service Lexington VA Health Care System  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lane","sequence":"additional","affiliation":[{"name":"Pharmacy Service Lexington VA Health Care System  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4638-054X","authenticated-orcid":false,"given":"Jennifer Meyer","family":"Reid","sequence":"additional","affiliation":[{"name":"Pharmacy Service Lexington VA Health Care System  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Guideline on Haemoglobin Cutoffs to Define Anaemia in Individuals and Populations [Internet]","year":"2024"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc\/168890"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2015.11.002"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010020\u201001022\u20102"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000034"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4488"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2450\/2018.0156\u201018"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi253"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.10.007"},{"key":"e_1_2_10_11_1","unstructured":"Veterans Health Administration \u201cVA.gov Home | Veterans Affairs \u201d(2025) https:\/\/www.va.gov\/health\/aboutVHA.asp."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_2_10_13_1","unstructured":"\u201cVA Informatics and Computing Infrastructure (VINCI) \u201d(2022) https:\/\/www.research.va.gov\/programs\/vinci\/."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097\u20100258(19980430)17:8<857::AID\u2010SIM777>3.0.CO;2\u2010E"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523\u20101755.2002.00314.x"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15572"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002779"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/M21\u20104009"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.08.020"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200629050\u201000003"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/JHQ.0000000000000481"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz261"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.102293"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q529"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70411","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70411","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:57:33Z","timestamp":1781585853000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/pds.70411"],"URL":"https:\/\/doi.org\/10.1002\/pds.70411","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70411"}}